2seven Bio

2seven Bio is a biotechnology company dedicated to developing a new class of bispecific immunotherapies that harness the power of Vδ2 (gamma delta 2) T cells to treat cancer. Launched by Apple Tree Partners (ATP) in 2022, the company leverages a proprietary platform to design engagers that specifically bridge Vδ2 T cells to tumor-associated antigens. This approach aims to exploit the potent, MHC-independent cytotoxic activity of gamma delta T cells while minimizing the systemic toxicity often associated with traditional T cell engagers. The company's pipeline includes programs targeting both solid tumors and hematologic malignancies. 2seven Bio is currently advancing its lead candidates through IND-enabling studies to bring these novel immunotherapies into clinical development.